RxDoctor Payments Data

Freida Toler

Family · Amarillo, TXNPI 1922306240

Payments from drug & device makers

$9,187in general payments, 2019–2025

Across 341 payments — averaging $26.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Amgen$1K
  • AbbVie$755
  • AstraZeneca$627
  • Boehringer Ingelheim$600
  • Lilly USA, LLC$592
  • plus $4K from 30 others

What the payments were for

  • Food & beverage$9,165100%
  • Education$220%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,187 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide127$189,019
MounjaroTirzepatide63$90,073
Tresiba Flextouch U-200Insulin Degludec49$80,984
JardianceEmpagliflozin52$63,097
Tresiba Flextouch U-100Insulin Degludec70$46,282
TrulicityDulaglutide27$42,617
FarxigaDapagliflozin Propanediol28$37,530
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog52$34,179
Fiasp FlextouchInsulin Aspart (Niacinamide)11$27,044
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog15$18,958
Lantus SolostarInsulin Glargine,hum.Rec.Anlog77$13,351
HumalogInsulin Lispro27$10,952
Humalog Kwikpen U-100Insulin Lispro22$10,537
ZenpepLipase/Protease/Amylase11$10,455
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/711$9,482

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Novolog$1,709$193,814140 claims
Lilly USA, LLCMounjaro, Trulicity, Humalog$592$143,642117 claims
Boehringer IngelheimJardiance$600$63,09752 claims
AstraZenecaFarxiga$627$37,53028 claims
Sanofi-aventis U.S. LLCLantus$317$5,50822 claims
AbbVieSynthroid$755$1,93237 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 15,456 family providers in Texas.

Other family in Amarillo

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →